Abstract:HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure–activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00346?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00346</a>.Tissue distributions profiles and plasma concentration–time curves in mice of 4r, 10m, and 19f; detailed experimental procedures for the synthesis of analogues 10a, 10b, 10i, 10j, 10k and intermediates 18h–18n; characterization (1H NMR spectra and 13C NMR spectra are attached) and HPLC purity control of the selected final compounds 10l, 10m, 18a, 18b, 18d, 18e, 18g, 19a–19h (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_001.pdf">PDF</a>)Molecular-formula strings of the reported compounds and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00346/suppl_file/jm0c00346_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

2-Arylthio-5-iodo Pyrimidine Derivatives As Non-Nucleoside HBV Polymerase Inhibitors

Study on 2-arylthio-5-iodo pyrimidine derivatives as novel nonnucleoside inhibitors against hepatitis B virus DNA replication.

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Synthesis of Janus Type Nucleoside Analogues and Their Preliminary Bioactivity

5-Iodo-2-arylalkylthio-6-aryl pyrimidin-4(3H)-ones as non-nucleoside anti-HBV agents

Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay

Design, synthesis, and biological evaluation of novel (E)-1-arylethan-1-one O-((3-arylisoxazol-5-yl) methyl) oxime derivatives as potent non-nucleoside HBV inhibitors

Optimization and Synthesis of Pyridazinone Derivatives As Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation

Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents

2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1h)-one Derivatives As Anti-Hbv Agents Targeting at Capsid Assembly

Panaxadiol and panaxatriol derivatives as anti-hepatitis B virus inhibitors

A Novel Pyridazinone Derivative Inhibits Hepatitis B Virus Replication by Inducing Genome-Free Capsid Formation

Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors

Structure-Based Discovery of <i>N</i>-Sulfonylpiperidine-3-Carboxamides as Novel Capsid Assembly Modulators for Potent Inhibition of HBV Replication

N-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H

Synthesis and Anti-Hepatitis B Virus Activity of Novel Benzimidazole Derivatives

Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus.

Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors

Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

Synthesis And Biological Evaluation Of Novel 5-Alkyl-2-Arylthio-6-((3,4-Dihydroquinolin-1(2h)-Yl)Methyl)Pyrimidin-4(3 H)-Ones As Potent Non-Nucleoside Hiv-1 Reverse Transcriptase Inhibitors

Synthesis and Anti-HBV Activity of Novel 3′-N-phenylsulfonyl Docetaxel Analogs